Pfizer (NYSE:PFE): Closing price $26.83
Pfizer’s partner GlycoMimetics has concluded the enrollment of patients in its Phase 2 study of GMI-1070, its lead investigational drug candidate. This randomized, double-blinded evaluation examined the efficacy, safety and pharmacokinetics of GMI-1070 in hospitalized sickle cell disease patients experiencing vaso-occlusive crisis. GlycoMimetics has enrolled 76 patients from the ages of 12 through 65 at 22 trial sites in the United States and Canada. The company expects topline data in the second quarter.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>